These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23684388)

  • 21. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
    Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Falcone M; Russo A; Venditti M; Novelli A; Pai MP
    Clin Infect Dis; 2013 Dec; 57(11):1568-76. PubMed ID: 24046298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
    Rand KH; Houck HJ
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2871-5. PubMed ID: 15273094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus.
    Leonard SN; Rolek KM
    J Antimicrob Chemother; 2013 Mar; 68(3):644-7. PubMed ID: 23152482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model.
    Cha R; Rybak MJ
    J Antimicrob Chemother; 2004 Jul; 54(1):259-62. PubMed ID: 15150172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
    Skiest DJ
    J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
    Vikram HR; Havill NL; Koeth LM; Boyce JM
    J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
    Louie A; Kaw P; Liu W; Jumbe N; Miller MH; Drusano GL
    Antimicrob Agents Chemother; 2001 Mar; 45(3):845-51. PubMed ID: 11181370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.
    Benvenuto M; Benziger DP; Yankelev S; Vigliani G
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3245-9. PubMed ID: 17005801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.
    Sader HS; Watters AA; Fritsche TR; Jones RN
    J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daptomycin: a review 4 years after first approval.
    Sauermann R; Rothenburger M; Graninger W; Joukhadar C
    Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.